We also have a research and development facility in Cambridge, Massachusetts. Eagle believes it can fully respond to the questions raised. There is one additional short duration study that will need to be completed and analyzed. The study will be run either in mid-February or mid-March. Disruption of certain intracellular mechanisms may affect cell functioning and survival. Our StrategyOur goal is to be a leading specialty pharmaceutical company. We entered into the Cephalon License to market this product. If approved, Ryanodex would represent the first product available for this indication. Alimta\'s lyophilized formulation utilizes pemetrexed disodium. On October 27, 2017, we were granted tentative approval for EP-5101 by the FDA. Under the terms of this Agreement no further milestone payments are due to Robert One. In addition, our clinical trials have been affected by COVID-19. As a result of the foregoing, we may incur losses and negative cash flows in the future. For example, the Tax Act enacted many significant changes to the U.S. tax laws. Our approved products may not achieve expected levels of market acceptance. This is also the case with respect to our other product candidates. Litigation may be necessary to defend against these claims. These stockholders may be able to influence all matters requiring stockholder approval.
